{
  "success": true,
  "pagesUsed": [
    1,
    7,
    8,
    20,
    23
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "PROTOCOL SUMMARY",
        "text": "PROTOCOL SUMMARY",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "N/A",
        "sectionTitle": "PROTOCOL SUMMARY",
        "sectionType": {
          "id": "617cbff2-6054-4708-a15d-8724b29bbe13",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "SCHEDULE OF ACTIVITIES",
        "text": "SCHEDULE OF ACTIVITIES",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "N/A",
        "sectionTitle": "SCHEDULE OF ACTIVITIES",
        "sectionType": {
          "id": "95c3c96c-6773-49f8-9bf5-e3a15ce44603",
          "code": "Study Procedures",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Procedures",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_3",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "b3a86271-093c-4cbf-93af-7b74ced59781",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_3_1",
          "nci_3_2",
          "nci_3_3"
        ]
      },
      {
        "id": "nc_4",
        "name": "STUDY OBJECTIVES AND ENDPOINTS",
        "text": "STUDY OBJECTIVES AND ENDPOINTS",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "STUDY OBJECTIVES AND ENDPOINTS",
        "sectionType": {
          "id": "7d5e7a08-f9e6-462d-9a0b-13c543f8f032",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2"
        ]
      },
      {
        "id": "nc_5",
        "name": "STUDY DESIGN",
        "text": "STUDY DESIGN",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN",
        "sectionType": {
          "id": "9883e994-d8b0-452a-a5c9-b7be7029de4f",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1"
        ]
      },
      {
        "id": "nc_6",
        "name": "PATIENT SELECTION",
        "text": "PATIENT SELECTION",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "PATIENT SELECTION",
        "sectionType": {
          "id": "5c803d56-48e4-4375-96f7-0dfd69ef27fc",
          "code": "Eligibility Criteria",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Eligibility Criteria",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_7",
        "name": "ECOG Performance Status",
        "text": "ECOG Performance Status",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "ECOG Performance Status",
        "sectionType": {
          "id": "6b396f7c-1e54-4f87-af12-b056c9c856bd",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_8",
        "name": "Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Guidelines",
        "text": "Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Guidelines",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Guidelines",
        "sectionType": {
          "id": "bb5163be-86ff-4738-8025-76796373973c",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_9",
        "name": "Immune related Response Criteria Derived from RECIST 1.1 (irRECIST)",
        "text": "Immune related Response Criteria Derived from RECIST 1.1 (irRECIST)",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Immune related Response Criteria Derived from RECIST 1.1 (irRECIST)",
        "sectionType": {
          "id": "4c3013c7-7bf6-49b5-89bf-5d904e3ef584",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_10",
        "name": "FACT-Kidney Symptom Index (FKSI)-19",
        "text": "FACT-Kidney Symptom Index (FKSI)-19",
        "order": 9,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "FACT-Kidney Symptom Index (FKSI)-19",
        "sectionType": {
          "id": "13e57c02-221a-4fc7-a27b-4d231dda3359",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_11",
        "name": "Euro Qol 5-Dimension (EQ-5D)",
        "text": "Euro Qol 5-Dimension (EQ-5D)",
        "order": 10,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Euro Qol 5-Dimension (EQ-5D)",
        "sectionType": {
          "id": "5541f1cd-66a7-428f-b24a-aac63c30e64e",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_12",
        "name": "National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)",
        "text": "National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)",
        "order": 11,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)",
        "sectionType": {
          "id": "d5132629-30e6-49e8-be6f-3b90f0d6c31d",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_13",
        "name": "Abbreviations and Definitions of Terms",
        "text": "Abbreviations and Definitions of Terms",
        "order": 12,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Abbreviations and Definitions of Terms",
        "sectionType": {
          "id": "0b020eb7-547c-4910-af16-8379a69aa3a0",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_14",
        "name": "Treatment Recommendations for Symptoms of Infusion-Related Reactions Caused by Avelumab",
        "text": "Treatment Recommendations for Symptoms of Infusion-Related Reactions Caused by Avelumab",
        "order": 13,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Treatment Recommendations for Symptoms of Infusion-Related Reactions Caused by Avelumab",
        "sectionType": {
          "id": "3867a551-6b27-49cf-ae5a-25cbd7b8a7ff",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_3_1",
        "name": "Mechanism of Action/Indication",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Mechanism of Action/Indication"
      },
      {
        "id": "nci_3_2",
        "name": "Background and Rationale",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Background and Rationale"
      },
      {
        "id": "nci_3_3",
        "name": "Summary of Benefit/Risk Assessment",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Summary of Benefit/Risk Assessment"
      },
      {
        "id": "nci_4_1",
        "name": "Objectives",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Objectives"
      },
      {
        "id": "nci_4_2",
        "name": "Endpoints",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Endpoints"
      },
      {
        "id": "nci_5_1",
        "name": "Study Overview",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Study Overview"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "RCC",
        "expandedText": "Renal cell carcinoma",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "IFN-α",
        "expandedText": "interferon-alpha",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "IL",
        "expandedText": "interleukin",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "aRCC",
        "expandedText": "advanced RCC",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "VEGF",
        "expandedText": "Vascular Endothelial Growth Factor",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "mTOR",
        "expandedText": "Mammalian Target of Rapamycin",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "VEGFR",
        "expandedText": "VEGF receptor",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "TKIs",
        "expandedText": "Tyrosine Kinase Inhibitors",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "PD-1",
        "expandedText": "Programmed cell Death protein-1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "PD-L1",
        "expandedText": "Programmed Death-Ligand 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "TILs",
        "expandedText": "tumor-infiltrating lymphocytes",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "mAb",
        "expandedText": "Monoclonal antibodies",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "ORR",
        "expandedText": "objective response rate",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "PFS",
        "expandedText": "progression-free survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "ASCO",
        "expandedText": "American Society of Clinical Oncology",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "Q3W",
        "expandedText": "every 3 weeks",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "DR",
        "expandedText": "duration of response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "CI",
        "expandedText": "confidence interval",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "BICR",
        "expandedText": "blinded independent central review",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "OS",
        "expandedText": "Overall Survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "HR",
        "expandedText": "Hazard Ratio",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "TLS",
        "expandedText": "Tumor Lysis Syndrome",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "ECOG",
        "expandedText": "Eastern Cooperative Oncology Group",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "RECIST",
        "expandedText": "Response Evaluation Criteria in Solid Tumors",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "irRECIST",
        "expandedText": "Immune related Response Criteria Derived from RECIST 1.1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "FACT-Kidney",
        "expandedText": "Functional Assessment of Cancer Therapy-Kidney",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "FKSI",
        "expandedText": "FACT-Kidney Symptom Index",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "EQ-5D",
        "expandedText": "Euro Qol 5-Dimension",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "NCI",
        "expandedText": "National Cancer Institute",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "CTCAE",
        "expandedText": "Common Terminology Criteria for Adverse Events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "FFPE",
        "expandedText": "Formalin-Fixed Paraffin-Embedded",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "PE",
        "expandedText": "Physical Examination",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_33",
        "abbreviatedText": "PS",
        "expandedText": "Performance Status",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 14,
      "itemCount": 6,
      "abbreviationCount": 33
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3, Multinational, Randomized, Open-Label Study to Evaluate Efficacy and Safety of Avelumab (MSB0010718C) in Combination with Axitinib Versus Sunitinib Monotherapy as First-Line Treatment in Patients with Advanced Renal Cell Carcinoma",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment 8",
      "versionDate": "03 January 2020",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9",
        "nc_10",
        "nc_11",
        "nc_12",
        "nc_13",
        "nc_14"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "RCC",
          "expansion": "Renal cell carcinoma"
        },
        {
          "abbreviation": "IFN-α",
          "expansion": "interferon-alpha"
        },
        {
          "abbreviation": "IL",
          "expansion": "interleukin"
        },
        {
          "abbreviation": "aRCC",
          "expansion": "advanced RCC"
        },
        {
          "abbreviation": "VEGF",
          "expansion": "Vascular Endothelial Growth Factor"
        },
        {
          "abbreviation": "mTOR",
          "expansion": "Mammalian Target of Rapamycin"
        },
        {
          "abbreviation": "VEGFR",
          "expansion": "VEGF receptor"
        },
        {
          "abbreviation": "TKIs",
          "expansion": "Tyrosine Kinase Inhibitors"
        },
        {
          "abbreviation": "PD-1",
          "expansion": "Programmed cell Death protein-1"
        },
        {
          "abbreviation": "PD-L1",
          "expansion": "Programmed Death-Ligand 1"
        },
        {
          "abbreviation": "TILs",
          "expansion": "tumor-infiltrating lymphocytes"
        },
        {
          "abbreviation": "mAb",
          "expansion": "Monoclonal antibodies"
        },
        {
          "abbreviation": "ORR",
          "expansion": "objective response rate"
        },
        {
          "abbreviation": "PFS",
          "expansion": "progression-free survival"
        },
        {
          "abbreviation": "ASCO",
          "expansion": "American Society of Clinical Oncology"
        },
        {
          "abbreviation": "Q3W",
          "expansion": "every 3 weeks"
        },
        {
          "abbreviation": "DR",
          "expansion": "duration of response"
        },
        {
          "abbreviation": "CI",
          "expansion": "confidence interval"
        },
        {
          "abbreviation": "BICR",
          "expansion": "blinded independent central review"
        },
        {
          "abbreviation": "OS",
          "expansion": "Overall Survival"
        },
        {
          "abbreviation": "HR",
          "expansion": "Hazard Ratio"
        },
        {
          "abbreviation": "TLS",
          "expansion": "Tumor Lysis Syndrome"
        },
        {
          "abbreviation": "ECOG",
          "expansion": "Eastern Cooperative Oncology Group"
        },
        {
          "abbreviation": "RECIST",
          "expansion": "Response Evaluation Criteria in Solid Tumors"
        },
        {
          "abbreviation": "irRECIST",
          "expansion": "Immune related Response Criteria Derived from RECIST 1.1"
        },
        {
          "abbreviation": "FACT-Kidney",
          "expansion": "Functional Assessment of Cancer Therapy-Kidney"
        },
        {
          "abbreviation": "FKSI",
          "expansion": "FACT-Kidney Symptom Index"
        },
        {
          "abbreviation": "EQ-5D",
          "expansion": "Euro Qol 5-Dimension"
        },
        {
          "abbreviation": "NCI",
          "expansion": "National Cancer Institute"
        },
        {
          "abbreviation": "CTCAE",
          "expansion": "Common Terminology Criteria for Adverse Events"
        },
        {
          "abbreviation": "FFPE",
          "expansion": "Formalin-Fixed Paraffin-Embedded"
        },
        {
          "abbreviation": "PE",
          "expansion": "Physical Examination"
        },
        {
          "abbreviation": "PS",
          "expansion": "Performance Status"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3, Multinational, Randomized, Open-Label Study to Evaluate Efficacy and Safety of Avelumab (MSB0010718C) in Combination with Axitinib Versus Sunitinib Monotherapy as First-Line Treatment in Patients with Advanced Renal Cell Carcinoma",
        "version": "Amendment 8",
        "versionDate": "03 January 2020"
      },
      "sections": [
        {
          "number": "N/A",
          "title": "PROTOCOL SUMMARY",
          "type": "Synopsis"
        },
        {
          "number": "N/A",
          "title": "SCHEDULE OF ACTIVITIES",
          "type": "Study Procedures"
        },
        {
          "number": "1",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Mechanism of Action/Indication"
            },
            {
              "number": "1.2",
              "title": "Background and Rationale",
              "subsections": [
                {
                  "number": "1.2.1",
                  "title": "Renal Cell Carcinoma"
                },
                {
                  "number": "1.2.2",
                  "title": "Pharmaceutical and Therapeutic Background"
                },
                {
                  "number": "1.2.3",
                  "title": "Rationale for Studying Avelumab in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma"
                },
                {
                  "number": "1.2.4",
                  "title": "Rationale for Avelumab, Axitinib, and Sunitinib Starting Dosing Regimens"
                }
              ]
            },
            {
              "number": "1.3",
              "title": "Summary of Benefit/Risk Assessment"
            }
          ]
        },
        {
          "number": "2",
          "title": "STUDY OBJECTIVES AND ENDPOINTS",
          "type": "Objectives",
          "subsections": [
            {
              "number": "2.1",
              "title": "Objectives"
            },
            {
              "number": "2.2",
              "title": "Endpoints"
            }
          ]
        },
        {
          "number": "3",
          "title": "STUDY DESIGN",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Study Overview",
              "subsections": [
                {
                  "number": "3.1.1",
                  "title": "Study Treatment"
                },
                {
                  "number": "3.1.2",
                  "title": "Tumor Assessments"
                },
                {
                  "number": "3.1.3",
                  "title": "Safety Assessments"
                },
                {
                  "number": "3.1.4",
                  "title": "Patient Outcomes"
                },
                {
                  "number": "3.1.5",
                  "title": "Pharmacokinetic/Immunogenicity Assessments"
                },
                {
                  "number": "3.1.6",
                  "title": "Biomarker Assessments"
                }
              ]
            }
          ]
        },
        {
          "number": "4",
          "title": "PATIENT SELECTION",
          "type": "Eligibility Criteria"
        },
        {
          "number": "Appendix 1",
          "title": "ECOG Performance Status",
          "type": "Appendix"
        },
        {
          "number": "Appendix 2",
          "title": "Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Guidelines",
          "type": "Appendix"
        },
        {
          "number": "Appendix 3",
          "title": "Immune related Response Criteria Derived from RECIST 1.1 (irRECIST)",
          "type": "Appendix"
        },
        {
          "number": "Appendix 4",
          "title": "FACT-Kidney Symptom Index (FKSI)-19",
          "type": "Appendix"
        },
        {
          "number": "Appendix 5",
          "title": "Euro Qol 5-Dimension (EQ-5D)",
          "type": "Appendix"
        },
        {
          "number": "Appendix 6",
          "title": "National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)",
          "type": "Appendix"
        },
        {
          "number": "Appendix 7",
          "title": "Abbreviations and Definitions of Terms",
          "type": "Appendix"
        },
        {
          "number": "Appendix 8",
          "title": "Treatment Recommendations for Symptoms of Infusion-Related Reactions Caused by Avelumab",
          "type": "Appendix"
        }
      ]
    }
  }
}